Analysts' ratings for Celldex Therapeutics (NASDAQ:CLDX) over the last quarter vary from bullish to bearish, as provided by 6 analysts.
In the table below, you'll find a summary of their recent ratings, revealing the shifting sentiments over the past 30 days and comparing them to the previous months.
| Bullish | Somewhat Bullish | Indifferent | Somewhat Bearish | Bearish | |
|---|---|---|---|---|---|
| Total Ratings | 4 | 1 | 0 | 1 | 0 |
| Last 30D | 0 | 0 | 0 | 1 | 0 |
| 1M Ago | 1 | 0 | 0 | 0 | 0 |
| 2M Ago | 3 | 1 | 0 | 0 | 0 |
| 3M Ago | 0 | 0 | 0 | 0 | 0 |
In the assessment of 12-month price targets, analysts unveil insights for Celldex Therapeutics, presenting an average target of $46.17, a high estimate of $62.00, and a low estimate of $25.00. This current average represents a 16.36% decrease from the previous average price target of $55.20.
Understanding Analyst Ratings: A Comprehensive Breakdown
The analysis of recent analyst actions sheds light on the perception of Celldex Therapeutics by financial experts. The following summary presents key analysts, their recent evaluations, and adjustments to ratings and price targets.
| Analyst | Analyst Firm | Action Taken | Rating | Current Price Target | Prior Price Target |
|---|---|---|---|---|---|
| Etzer Darout | Barclays | Announces | Underweight | $25.00 | - |
| Edward Nash | Canaccord Genuity | Maintains | Buy | $62.00 | $62.00 |
| Derek Archila | Wells Fargo | Lowers | Overweight | $38.00 | $44.00 |
| David Lebowitz | Citigroup | Lowers | Buy | $48.00 | $56.00 |
| Edward Nash | Canaccord Genuity | Lowers | Buy | $62.00 | $64.00 |
| Joseph Pantginis | HC Wainwright & Co. | Lowers | Buy | $42.00 | $50.00 |
Key Insights:
- Action Taken: Analysts adapt their recommendations to changing market conditions and company performance. Whether they 'Maintain', 'Raise' or 'Lower' their stance, it reflects their response to recent developments related to Celldex Therapeutics. This information provides a snapshot of how analysts perceive the current state of the company.
- Rating: Providing a comprehensive analysis, analysts offer qualitative assessments, ranging from 'Outperform' to 'Underperform'. These ratings reflect expectations for the relative performance of Celldex Therapeutics compared to the broader market.
- Price Targets: Delving into movements, analysts provide estimates for the future value of Celldex Therapeutics's stock. This analysis reveals shifts in analysts' expectations over time.
Navigating through these analyst evaluations alongside other financial indicators can contribute to a holistic understanding of Celldex Therapeutics's market standing. Stay informed and make data-driven decisions with our Ratings Table.
Stay up to date on Celldex Therapeutics analyst ratings.
If you are interested in following small-cap stock news and performance you can start by tracking it here.
About Celldex Therapeutics
Celldex Therapeutics Inc is a biopharmaceutical company. It is focused on the development and commercialization of several immunotherapy technologies and other cancer-targeting biologics. The company is also engaged in clinical trials for products targeting breast cancer, metastatic melanoma, lung cancer, solid tumors, and ovarian cancer. It has single operating and reportable segment that operates in the business of development, manufacturing and commercialization of novel therapeutics for human health care.
Celldex Therapeutics: A Financial Overview
Market Capitalization Analysis: The company's market capitalization surpasses industry averages, showcasing a dominant size relative to peers and suggesting a strong market position.
Decline in Revenue: Over the 3M period, Celldex Therapeutics faced challenges, resulting in a decline of approximately -70.78% in revenue growth as of 30 June, 2025. This signifies a reduction in the company's top-line earnings. As compared to its peers, the revenue growth lags behind its industry peers. The company achieved a growth rate lower than the average among peers in Health Care sector.
Net Margin: Celldex Therapeutics's net margin excels beyond industry benchmarks, reaching -7753.42%. This signifies efficient cost management and strong financial health.
Return on Equity (ROE): The company's ROE is a standout performer, exceeding industry averages. With an impressive ROE of -8.33%, the company showcases effective utilization of equity capital.
Return on Assets (ROA): Celldex Therapeutics's ROA lags behind industry averages, suggesting challenges in maximizing returns from its assets. With an ROA of -7.91%, the company may face hurdles in achieving optimal financial performance.
Debt Management: Celldex Therapeutics's debt-to-equity ratio is below the industry average at 0.0, reflecting a lower dependency on debt financing and a more conservative financial approach.
Analyst Ratings: Simplified
Within the domain of banking and financial systems, analysts specialize in reporting for specific stocks or defined sectors. Their work involves attending company conference calls and meetings, researching company financial statements, and communicating with insiders to publish "analyst ratings" for stocks. Analysts typically assess and rate each stock once per quarter.
Some analysts also offer predictions for helpful metrics such as earnings, revenue, and growth estimates to provide further guidance as to what to do with certain tickers. It is important to keep in mind that while stock and sector analysts are specialists, they are also human and can only forecast their beliefs to traders.
Breaking: Wall Street's Next Big Mover
Benzinga's #1 analyst just identified a stock poised for explosive growth. This under-the-radar company could surge 200%+ as major market shifts unfold. Click here for urgent details.
This article was generated by Benzinga's automated content engine and reviewed by an editor.
© 2025 Benzinga.com. Benzinga does not provide investment advice. All rights reserved.
